Click here to get full coverage on Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan

Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026  Stock Titan

Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan

Click here to get full coverage on Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus

Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced  GuruFocus

Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why - MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why  MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why - MarketBeat

Click here to get full coverage on Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates  Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView

Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer  TradingView

Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView

Click here to get full coverage on Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration - simplywall.st

Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration  simplywall.st

Why Crinetics Pharmaceuticals (CRNX) Is Down 7.1% After Deeper 2025 Loss And New US$207 Million Shelf Registration - simplywall.st

Click here to get full coverage on CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison  Intellectia AI

CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Click here to get full coverage on Crinetics Pharma COO to step down - MSN

Crinetics Pharma COO to step down - MSN

Click here to get full coverage on Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback - Yahoo Finance

Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback  Yahoo Finance

Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback - Yahoo Finance

Click here to get full coverage on CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan

CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise  Stock Titan

CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan

Click here to get full coverage on Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Sells 9,911 Shares of Stock - MarketBeat

Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Sells 9,911 Shares of Stock  MarketBeat

Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Sells 9,911 Shares of Stock - MarketBeat

Click here to get full coverage on Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - simplywall.st

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility  simplywall.st

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - simplywall.st

Click here to get full coverage on Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential - Yahoo Finance

Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential  Yahoo Finance

Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential - Yahoo Finance

Click here to get full coverage on Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan

Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes  Stock Titan

Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock  MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat

Click here to get full coverage on Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - simplywall.st

Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now?  simplywall.st

Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - simplywall.st

Click here to get full coverage on Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan

Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax  Stock Titan

Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan

Click here to get full coverage on Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives - simplywall.st

Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives  simplywall.st

Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives - simplywall.st

Click here to get full coverage on Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan

Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan  Stock Titan

Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan

Click here to get full coverage on Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Yahoo Finance

Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral  Yahoo Finance

Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Yahoo Finance

Click here to get full coverage on Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade - Stock Titan

Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade  Stock Titan

Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade - Stock Titan

Click here to get full coverage on Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Yahoo Finance

Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug  Yahoo Finance

Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Yahoo Finance

Click here to get full coverage on [144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan

[144] Crinetics Pharmaceuticals, Inc. SEC Filing  Stock Titan

[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan

Click here to get full coverage on Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - Sahm

Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now?  Sahm

Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - Sahm

Click here to get full coverage on CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill

CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX)  ChartMill

CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill

Click here to get full coverage on 10 new Crinetics workers get stock awards vesting over 4 years - Stock Titan

10 new Crinetics workers get stock awards vesting over 4 years  Stock Titan

10 new Crinetics workers get stock awards vesting over 4 years - Stock Titan

Click here to get full coverage on Live briefing to share atumelnant results in congenital adrenal hyperplasia - Stock Titan

Live briefing to share atumelnant results in congenital adrenal hyperplasia  Stock Titan

Live briefing to share atumelnant results in congenital adrenal hyperplasia - Stock Titan

Click here to get full coverage on JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - Yahoo Finance

JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval  Yahoo Finance

JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - Yahoo Finance

Click here to get full coverage on Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN

Jim Cramer on Crinetics: “That’s a better spec than Aquestive”  MSN

Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN

Click here to get full coverage on Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data  Yahoo Finance

Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance

Click here to get full coverage on Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan - Stock Titan

Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan  Stock Titan

Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow - Seeking Alpha

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow  Seeking Alpha

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow - Seeking Alpha

Click here to get full coverage on Crinetics (NASDAQ: CRNX) CFO sells 6,713 shares to cover taxes - Stock Titan

Crinetics (NASDAQ: CRNX) CFO sells 6,713 shares to cover taxes  Stock Titan

Crinetics (NASDAQ: CRNX) CFO sells 6,713 shares to cover taxes - Stock Titan

Click here to get full coverage on Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq

Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX)  Nasdaq

Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq

Click here to get full coverage on JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating - Yahoo Finance

JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating  Yahoo Finance

JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating - Yahoo Finance

Click here to get full coverage on Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX  MarketBeat

Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Click here to get full coverage on Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat

Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00  MarketBeat

Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat

Click here to get full coverage on Checkpoint Capital L.P. Purchases Shares of 260,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Checkpoint Capital L.P. Purchases Shares of 260,000 Crinetics Pharmaceuticals, Inc. $CRNX  MarketBeat

Checkpoint Capital L.P. Purchases Shares of 260,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Click here to get full coverage on $CRNX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

$CRNX stock is up 9% today. Here's what we see in our data.  Quiver Quantitative

$CRNX stock is up 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Yahoo Finance

Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler  Yahoo Finance

Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Yahoo Finance

Click here to get full coverage on New acromegaly pill brings in $5.4M as Europe review advances - Stock Titan

New acromegaly pill brings in $5.4M as Europe review advances  Stock Titan

New acromegaly pill brings in $5.4M as Europe review advances - Stock Titan

Click here to get full coverage on Those who invested in Crinetics Pharmaceuticals (NASDAQ:CRNX) five years ago are up 151% - Yahoo Finance

Those who invested in Crinetics Pharmaceuticals (NASDAQ:CRNX) five years ago are up 151%  Yahoo Finance

Those who invested in Crinetics Pharmaceuticals (NASDAQ:CRNX) five years ago are up 151% - Yahoo Finance

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS  MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Click here to get full coverage on CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Stocktwits

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial  Stocktwits

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial - Stocktwits

Click here to get full coverage on Biotech plans $350M raise to launch PALSONIFY and fund R&D - Stock Titan

Biotech plans $350M raise to launch PALSONIFY and fund R&D  Stock Titan

Biotech plans $350M raise to launch PALSONIFY and fund R&D - Stock Titan

Click here to get full coverage on Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates  Yahoo Finance

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Rafferty Asset Management LLC Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Rafferty Asset Management LLC Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX  MarketBeat

Rafferty Asset Management LLC Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen  MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat

Click here to get full coverage on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts  MarketBeat

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on CRNX: Palsinify's successful launch and robust pipeline position the business for sustained growth - TradingView

CRNX: Palsinify's successful launch and robust pipeline position the business for sustained growth  TradingView

CRNX: Palsinify's successful launch and robust pipeline position the business for sustained growth - TradingView

Click here to get full coverage on Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX) - The Globe and Mail

Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)  The Globe and Mail

Goldman Sachs Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX) - The Globe and Mail

Click here to get full coverage on New trial tests once-daily pill for rare adrenal disorder in kids - Stock Titan

New trial tests once-daily pill for rare adrenal disorder in kids  Stock Titan

New trial tests once-daily pill for rare adrenal disorder in kids - Stock Titan

Click here to get full coverage on Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock - MarketBeat

Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock  MarketBeat

Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock - MarketBeat

Click here to get full coverage on Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug - Yahoo Finance

Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug  Yahoo Finance

Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug - Yahoo Finance

Click here to get full coverage on Crinetics Progresses Rare Endocrine Pipeline With New Data And Early Sales - simplywall.st

Crinetics Progresses Rare Endocrine Pipeline With New Data And Early Sales  simplywall.st

Crinetics Progresses Rare Endocrine Pipeline With New Data And Early Sales - simplywall.st

Click here to get full coverage on Crinetics (CRNX) CEO receives major stock option and RSU awards - Stock Titan

Crinetics (CRNX) CEO receives major stock option and RSU awards  Stock Titan

Crinetics (CRNX) CEO receives major stock option and RSU awards - Stock Titan

Click here to get full coverage on CRNX FDA Catalyst Alert: Could Paltusotine Decision Reshape Endocrine Drug Market? - RTTNews

CRNX FDA Catalyst Alert: Could Paltusotine Decision Reshape Endocrine Drug Market?  RTTNews

CRNX FDA Catalyst Alert: Could Paltusotine Decision Reshape Endocrine Drug Market? - RTTNews

Click here to get full coverage on CRNX Stock Price, News & Analysis - Stock Titan

CRNX Stock Price, News & Analysis  Stock Titan

CRNX Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Should You Hold Crinetics Pharmaceuticals (CRNX)? - Yahoo Finance

Should You Hold Crinetics Pharmaceuticals (CRNX)?  Yahoo Finance

Should You Hold Crinetics Pharmaceuticals (CRNX)? - Yahoo Finance

Click here to get full coverage on (CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

(CRNX) as a Liquidity Pulse for Institutional Tactics  Stock Traders Daily

(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Click here to get full coverage on $CRNX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$CRNX stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$CRNX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Crinetics plans March appearances at TD Cowen and Leerink events - Stock Titan

Crinetics plans March appearances at TD Cowen and Leerink events  Stock Titan

Crinetics plans March appearances at TD Cowen and Leerink events - Stock Titan

Click here to get full coverage on Crinetics schedules Feb. 26 webcast on Q4 and 2025 financials - Stock Titan

Crinetics schedules Feb. 26 webcast on Q4 and 2025 financials  Stock Titan

Crinetics schedules Feb. 26 webcast on Q4 and 2025 financials - Stock Titan

Click here to get full coverage on First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX  MarketBeat

First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans  Yahoo Finance

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Click here to get full coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares - MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares  MarketBeat

Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Stephanie Okey Sells 3,000 Shares - MarketBeat

Click here to get full coverage on Insider Sale: Chief Commercial Officer of $CRNX Sells 2,500 Shares - Quiver Quantitative

Insider Sale: Chief Commercial Officer of $CRNX Sells 2,500 Shares  Quiver Quantitative

CRNX

Price Chart

Key Statistics

Technicals

About CRNX

Latest News

Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan

Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Here's Why - MarketBeat

Advanced Charts

Top Gainers

Top Losers